D-0149-2017 Class III Terminated

Recalled by Zydus Pharmaceuticals USA Inc — Pennington, NJ

FDA drug recall D-0149-2017 was initiated by Zydus Pharmaceuticals USA Inc on Aug 3, 2016 and is designated Class III. Reason for recall: Failed Dissolution Specifications: Product did not meet dissolution specification at an intermediate time point. The recall status is terminated (terminated Jul 12, 2018). Affected quantity: 2,472 units.

Recall details

Product Type
Drugs
Report Date
Nov 30, 2016
Initiation Date
Aug 3, 2016
Termination Date
Jul 12, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,472 units

Product description

BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 300 mg, Rx Only, 500-count bottles, Manufactured by Cadila Healthcare Ltd. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA inc. Pennington, NJ 08534, NDC 68382-354-05

Reason for recall

Failed Dissolution Specifications: Product did not meet dissolution specification at an intermediate time point.

Distribution pattern

Nationwide

Code information

Lot #: MR3365, Exp. Feb 17

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0149-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0149-2017. Report a data issue: hello@regdatalab.com.